Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 9,609 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (in-patient) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults

NCT04663139
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Xla1, Placebo
Drug
Lead sponsor
YSOPIA Bioscience
Industry
Eligibility
19 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

NCT04882124
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Andalusia, Alabama • Crowley, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 11, 2026, 10:52 PM EDT
Terminated Phase 4 Interventional Results available

Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer

NCT01459666
View directory record Official record
Conditions
Scar
Interventions
Dysport (abobotulinumtoxinA), Bacteriostatic 0.9% Sodium Chloride (vehicle)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Cleveland, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 11, 2026, 10:52 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

NCT02563522
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
Engensis (VM202), Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 3 Interventional

Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps

NCT00005094
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
celecoxib, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
30 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 11, 2026, 10:52 PM EDT
Recruiting Not applicable Interventional

Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

NCT05102929
View directory record Official record
Conditions
Schizophrenia
Interventions
active intermittent Theta Burst Stimulation (iTBS), sham intermittent Theta Burst Stimulation (iTBS)
Device
Lead sponsor
Fabio Ferrarelli
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT04166773
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Fresno, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 11, 2026, 10:52 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

NCT04828161
View directory record Official record
Conditions
COVID-19
Interventions
ensovibep, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
27
States / cities
Jasper, Alabama • Colton, California • Fullerton, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

NCT00456586
View directory record Official record
Conditions
Parkinson's Disease
Interventions
KW-6002 (istradefylline)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 11, 2026, 10:52 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

NCT06867094
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
SAR441566, SAR441566 matching Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
19
States / cities
Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 11, 2026, 10:52 PM EDT
Not yet recruiting Not applicable Interventional

NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty

NCT07439666
View directory record Official record
Conditions
Total Knee Arthroplasty Postoperative Pain, Opioid Reduction After TKA
Interventions
NEUROCUPLE™ Patch, Sham patch, Enhanced Recovery After Surgery (ERAS) Standard of Care
Device · Other
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 11, 2026, 10:52 PM EDT
Terminated Not applicable Interventional Results available

CASAD for Severe Diarrhea in the Emergency Department

NCT02018653
View directory record Official record
Conditions
Cancer, Diarrhea
Interventions
Calcium Alumina-Silicate (CASAD), Placebo, Questionnaire
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 11, 2026, 10:52 PM EDT
Terminated Phase 2 Interventional

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

NCT01673672
View directory record Official record
Conditions
Moderate to Severe Allergic Asthma
Interventions
CYT003, Placebo
Biological
Lead sponsor
Cytos Biotechnology AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

A Study for Participants With Type 2 Diabetes Mellitus

NCT00871572
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2409021, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Buena Park, California • Huntington Park, California • Westlake Village, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 11, 2026, 10:52 PM EDT
Recruiting Phase 2 Interventional

Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

NCT04721873
View directory record Official record
Conditions
Colitis, Ulcerative, Obesity
Interventions
Phentermine-Topiramate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

NCT00295854
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
MN-001 BID, MN-001, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Glendora, California • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 3 Interventional

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

NCT00003805
View directory record Official record
Conditions
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
2 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 11, 2026, 10:52 PM EDT
Not yet recruiting Phase 2 Interventional

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

NCT06710431
View directory record Official record
Conditions
Alcohol Abuse, Alcohol Abuse/addiction, Anxiety, Pain Threshold, Depression Disorders, Sleep Disorder
Interventions
AFA-281
Drug
Lead sponsor
Afasci Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 11, 2026, 10:52 PM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

NCT00814372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-102, Placebo, Actos, Metformin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Results available

Estrogen and Fear in PTSD

NCT04192266
View directory record Official record
Conditions
PTSD
Interventions
Estradiol, Placebo oral tablet, Prolonged Exposure (PE) therapy
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 4 Interventional Results available

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

NCT03081156
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler
Drug
Lead sponsor
William Stringer, md
Other
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions

NCT01834729
View directory record Official record
Conditions
Constipation
Interventions
Alfuzosin, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 11, 2026, 10:52 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone

NCT00970424
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Placebo, Dutogliptin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
89
States / cities
Birmingham, Alabama • Chandler, Arizona • Litchfield, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 11, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

NCT00201123
View directory record Official record
Conditions
Tuberculosis, AIDS-related Complex
Interventions
Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 11, 2026, 10:52 PM EDT